Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 1-2-3 Get In/Get Out - On Timely, Important News -- Ignore unavailable to you. Want to Upgrade?

To: Winston Kim who wrote (1012)	11/13/1997 10:15:00 AM
From: Paul Tran	Respond to of 1136

Diagnostic Products Corporation Receives FDA Clearance to Market IMMULITE Third Generation PSA Assay Thursday November 13, 6:32 am Eastern Time Company Press Release Diagnostic Products Corporation Receives FDA Clearance to Market IMMULITE Third Generation PSA Assay Highly Sensitive Test Provides Improvement In The Management of Prostate Cancer LOS ANGELES--(BW HealthWire)--Nov. 13, 1997-- Diagnostic Products Corporation (NYSE:DP - news) today announced that it has received FDA clearance for marketing of its IMMULITE Third Generation PSA assay, a new ultrasensitive method to aid in the management of prostate cancer patients. The company will begin shipments of the assay immediately to hospitals and clinical laboratories. The prostate-specific-antigen (PSA) is widely recognized as the most specific tumor marker generally available and a key indicator for the evaluation of prostate cancer. Diagnostic Products' IMMULITE Third Generation PSA assay has the lowest analytical detection limit and functional sensitivity commercially available. The assay is offered for use with Diagnostic Products' IMMULITE immunoassay analyzer, an automated random access system. ''Diagnostic Products' Third Generation PSA Assay is the most sensitive assay to date to be put on the market,'' said Thomas A. Stamey, M.D., and Professor of Urology at Stanford Medical Center. ''The assay's ultrasensitivity is a tremendous advantage in monitoring cancer patients, allowing clinicians an important time advantage in which to assess and treat patients. Also, the results gained through this assay can be reassuring to patients, who are understandably concerned whether their cancer has been successfully treated.'' ''This approval marks a significant addition to the urologists' armamentarium,'' said Michael Ziering, president of Diagnostic Products Corporation. ''With estimates showing that one in five American men will develop prostate cancer in their lifetime, the ultrasensitive Third Generation PSA Assay will provide clinicians with important immunodiagnostic information during the monitoring of their cancer patients. The new assay provides a solid growth opportunity for Diagnostic Products in the fast-growing urology market and further expands the company's IMMULITE product line.'' Founded in 1971, Diagnostic Products Corporation (DPC) develops, produces, and supports a wide variety of immunodiagnostic products for clinical and research laboratories. It is one of the world's fastest growing in vitro diagnostic manufacturers for automated immunoassay systems and reagents, and is the worldwide leader in fertility assays. With over 300 tests, DPC's products are used by hospitals, as well as clinical, forensic, research and veterinary laboratories domestically and in more than 100 foreign countries. More Quotes and News: Diagnostic Products Corp (NYSE:DP - news) Related News Categories: biotech, medical/pharmaceutical

To: Winston Kim who wrote (1012)	11/13/1997 10:21:00 AM
From: Paul Tran	Read Replies (1) \| Respond to of 1136

EndoSonics Receives 510-K Clearance for the Cardiometrics FloWire 300 and FloWire 300XT Doppler Guide Wires RANCHO CORDOVA, Calif.--(BW HealthWire)--Nov. 13, 1997-- EndoSonics Corporation (NASDAQ:ESON - news), a leading developer and marketer of intravascular ultrasound and flow measurement products, today announced that it has received 510(k) marketing clearance from the United States Food and Drug Administration (FDA) for its FloWire(R) 300 and FloWire(R) 300 XT Doppler Guide wires for use with the Cardiometrics FloMap(R) Functional Assessment products. EndoSonics markets a line of guide wire-based doppler ultrasound devices as part of its Cardiometrics product line, which was acquired in July 1997. The FloWire 300 and the FloWire 300XT are designed to enable catheter exchanges during cardiovascular intervention, which allows for stent deployment and alternative balloon therapies. Prior to this approval action, physicians were limited in their ability to change their therapeutic strategy in the middle of the procedure. This FDA action allows the physician to begin a procedure with one catheter, and then switch to a different catheter or stent during the procedure without removing the FloWire(R). ''The clearance of the FloWire 300 and FloWire 300XT in less than 90 days was a major achievement,'' said Reinhard Warnking, president and CEO of EndoSonics. ''We believe that this product will provide significant benefit to the clinician in assessing the state of patient conditions and the result of therapeutic interventions, and will provide this information in a manner consistent with the current trend toward stent-based interventions. ''The recent approval by FDA of several intracoronary stents, and the published information on the utility of physiologic assessment during the placement of these devices, increases the importance of the ability to quickly obtain quantitative information from within the coronary vasculature. The addition of these longer exchange length wire products is an important tool in the expansion of this technique.'' EndoSonics develops, manufactures and markets intravascular ultrasound (IVUS) imaging systems and catheters to assist in the diagnosis and treatment of cardiovascular and peripheral vascular disease. EndoSonics' IVUS imaging products enhance the effectiveness of the diagnosis and treatment of the coronary artery by providing important diagnostic information not available from conventional x-ray angiography. The information includes the location, amount and composition of atherosclerotic plaque and enables physicians to identify lesion characteristics, select an optimum form of treatment, position therapeutic devices and promptly assess the results of treatment. The recently completed merger of Cardiometrics, Inc. adds products that measure blood flow impairment caused by coronary artery disease. Cardometrics' principal products, the FloWire(R) Doppler guide wire and FloMap(R) ultrasound instrument, represent a significant clinical advance -- on-line functional testing of blood flow impairment in the Cath Lab -- enabling cardiologists to evaluate the appropriateness of angioplasty interventions and assess post-procedural results. For additional information on EndoSonics, please visit our Web site at endosonics.com . This press release contains forward-looking statements that involve risks and uncertainties. The company's actual results may differ significantly from the results discussed in the forward-looking statements. For a discussion of factors that might result in different outcomes, see the company's Form 10K/A, form 10-Q, and the Registration Statement on Form S-4 filed with the Securities and Exchange Commission on June 13, 1997. More Quotes and News: Endosonics Corp (Nasdaq:ESON - news) Related News Categories: computers, medical/pharmaceutical